The in vitro activity of Cabozantinib as first- and second-line agent in metastatic renal cell carcinoma

被引：0
|
作者：
Zaccagnino, Angela [1 ]
Vynnytska-Myronovska, Bozhena [2 ]
Stoeckle, Michael [1 ]
Junker, Kerstin [1 ]
机构：
[1] Saarland Univ, Dept Urol & Pediat Urol, Homburg, Germany
[2] Univ Saarland, Homburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
195
引用
收藏
页码：102 / 102
页数：1
相关论文
共 50 条
  • [41] Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma
    Ueda, Kosuke
    Suekane, Shigetaka
    Hirano, Taishi
    Ogasawara, Naoyuki
    Chikui, Katsuaki
    Uemura, Keiichiro
    Nakiri, Makoto
    Nishihara, Kiyoaki
    Matsuo, Mitsunori
    Igawa, Tsukasa
    ANTICANCER RESEARCH, 2018, 38 (09) : 5387 - 5392
  • [42] Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma
    Alekseev, B. Ya.
    Shevchuk, I. M.
    Kaprin, A. D.
    ONKOUROLOGIYA, 2018, 14 (02): : 68 - 78
  • [43] Sorafenib as second-line treatment in metastatic renal cell carcinoma: A prospective cohort.
    Martin Aguilar, Ana Elena
    Nayeli Nunez-Lopez, Haide
    Carlos Ramirez-Sandoval, Juan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies
    Rebibo, J. D.
    Pfister, C.
    Giwerc, A.
    Defortescu, G.
    Gouerant, S.
    Di Fiore, F.
    Nouhaud, F. -X.
    PROGRES EN UROLOGIE, 2016, 26 (01): : 16 - 23
  • [45] Second-line cabozantinib versus nivolumab in advanced renal cell carcinoma: Systematic review and indirect treatment comparison
    Porta, Camillo
    Szczylik, Cezary
    Casciano, Roman
    Fu, Shuai
    Amzal, Billy
    Lister, Johanna
    Karcher, Helene
    Meng, Jie
    Neumann, Monika
    Dinet, Jerome
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 139 : 143 - 148
  • [46] First- and second-line therapy for advanced nonsmall cell lung cancer
    Sculier, J-P.
    Moro-Sibilot, D.
    EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (04) : 915 - 930
  • [47] Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma
    Motzer, Robert J.
    Barrios, Carlos H.
    Kim, Tae Min
    Falcon, Silvia
    Cosgriff, Thomas
    Harker, W. Graydon
    Srimuninnimit, Vichien
    Pittman, Ken
    Sabbatini, Roberto
    Rha, Sun Young
    Flaig, Thomas W.
    Page, Ray
    Bavbek, Sevil
    Beck, J. Thaddeus
    Patel, Poulam
    Cheung, Foon-yiu
    Yadav, Sunil
    Schiff, Edward M.
    Wang, Xufang
    Niolat, Julie
    Sellami, Dalila
    Anak, Oezlem
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) : 2766 - +
  • [48] Is first- and second-line immunotherapy sequence the optimal strategy for unresectable hepatocellular carcinoma?
    Celsa, C.
    Cabibbo, G.
    Battaglia, S.
    Enea, M.
    Rizzo, G. E. M.
    Busacca, A.
    Stornello, C.
    Giuffrida, P.
    Craxi, A.
    Camma, C.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S33 - S33
  • [49] Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma
    Liu, Tong
    Jin, Yao
    Dong, Mei
    CLINICAL GENITOURINARY CANCER, 2023, 21 (06) : E449 - E460
  • [50] FIRST- AND SECOND-LINE TREATMENT PATTERNS IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK: A CHART REVIEW STUDY IN THREE COUNTRIES
    Gogate, A.
    Shillington, A. C.
    Dave, V
    Singh, P.
    VALUE IN HEALTH, 2022, 25 (12) : S287 - S287
12345